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Abstract
Objective: To investigate oxidative stress markers and antioxidants in bipolar disor-
der (BD).
Methods: Electronic MEDLINE/PubMed/Cochrane-Library/Scopus/TripDatabase 
search until 06/30/2019 for studies comparing antioxidant or oxidative stress mark-
ers between BD and healthy controls (HCs). Standardized mean differences (SMD) 
and 95% confidence intervals (CIs) were calculated for ≥3 studies.
Results: Forty-four studies (n = 3,767: BD = 1,979; HCs = 1,788) reported on oxida-
tive stress markers malondialdehyde (MDA), thiobarbituric acid reactive substances 
(TBARS), and total nitrites; antioxidants glutathione (GSH), uric acid, and zinc; or an-
tioxidantenhancing enzymes superoxide dismutase (SOD), catalase (CAT), glutathione 
peroxidase (GPX), and GSH-transferase (GST). Compared with HCs, BD was associated 
with higher GST (P = .01), CAT (P = .02), nitrites (P < .0001), TBARS (P < .0001), MDA 
(P = .01), uric acid (P < .0001), and lower GSH (P = .006), without differences in SOD, 
GPX, and zinc. Compared to HCs, levels were higher in BD-mania for TBARS (P < .0001) 
and uric acid (P < .0001); in BD-depression for TBARS (P = .02); and BD-euthymia for 
uric acid (P = .03). Uric acid levels were higher in BD-mania vs BD-depression (P = .002), 
but not vs BD euthymia. TBARS did not differ between BD-mania and BD-depression. 
Medication-free BD-mania patients had higher SOD (P = .02) and lower GPX (P < .0001) 
than HCs. After treatment, BD did not differ from HCs regarding SOD and GPX.
Conclusions: Beyond a single biomarker of oxidative stress, the combination of sev-
eral parameters appears to be more informative for BD in general and taking into 
account illness polarity. BD is associated with an imbalance in oxidative stress with 
some phase-specificity for uric acid and TBARS and possible treatment benefits for 
SOD and GPX. Future studies should take into account confounding factors that can 
modify oxidative stress status and simultaneously measure oxidative stress markers 
and antioxidants including different blood sources.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
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1  | INTRODUC TION
Severe mental disorders as well as cardiovascular diseases are as-
sociated with high rates of disability and mortality.1-4 The reported 
lifetime prevalence in the United States and worldwide is 1.0% and 
0.6% for type I bipolar disorder (BD); 1.1% and 0.4% for type II BD;, 
and 2.4% and 1.4% of subthreshold BD.5,6 However, despite this 
relatively low prevalence, BD is associated with significant disabili-
ty-adjusted life years.7 Part of this disability is related to a higher risk 
of chronic systemic diseases, including cardiovascular diseases.8-12 
This co-occurrence could be due to common genetic13 or biological 
alterations, including immune-inflammatory pathways and oxidative 
stress pathways that are closely related.14-17
Oxidative stress consists of an imbalance between oxidant and 
antioxidant species,18 such as the antioxidant enzymes catalase 
(CAT) or superoxide dismutase (SOD), and the non-enzymatic anti-
oxidant uric acid or bilirubin, among others.18,19 Reactive species are 
products of normal physiological functioning, synthetized during 
the mitochondria cellular respiration, and play an important role in 
the cellular response against internal or external toxins in moderate 
and low concentrations.20 In high concentrations, however, radical 
species attack different compounds of living cells, such as DNA, lip-
ids, and proteins,19,21,22 resulting in cell death and apoptosis. The 
products resulting from the free radical attack can be assessed to 
determine the oxidative stress status of the body (Figure 1).
Evidence suggests elevated oxidative stress among BD pa-
tients.23 Moreover, mood stabilizers, such as lithium and valproate,23 
have antioxidant and anti-inflammatory effects,24,25 which may also 
relate to their efficacy, protecting brain cells from dysfunction and 
apoptosis, while enhancing brain-derived neurotrophic factor.23
Oxidative stress quite likely contributes to diminished neuro-
plasticity and neurogenesis, and increased apoptosis and neuro-
degeneration in BD and depression.26,27 Structural brain changes 
appear in BD patients before disease onset,26,27 at times of dys-
functions in neurotransmitter reuptake and enzyme activities.28 
Moreover, the frequency and duration of BD episodes seem to 
be associated with cognitive deficits, which relate to neuropro-
gression.29,30 However, the exact implication of oxidative stress 
pathways in these processes is still unknown. The total antioxidant 
capacity decreases after a first episode of mania, whereas antiox-
idant mechanisms either do not change regardless of the number 
of manic episodes, or even increase at later stages of BD, like for 
example with GST and GR.26,27
Therefore, in order to prevent the cognitive and functional 
consequences of BD it is necessary to make the correct diagnosis 
and to prescribe the correct treatment in the early phases of the 
disease. To this end, new and reliable biomarkers should be devel-
oped in Psychiatry to identify different disease stages just as other 
medical specialties do in their everyday clinical practice.31 Although 
different studies point to alterations in antioxidant enzymes among 
patients with BD,32-34 two previous meta-analyses showed no sig-
nificant differences in the antioxidant-enzyme defenses in patients 
with BD compared to healthy controls (HCs).35,36 Nevertheless, dif-
ferent affective phases of BD were not taken into account in these 
two meta-analyses, nor was the effect of different pharmacological 
treatments.
K E Y W O R D S
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F I G U R E  1   Oxidative stress pathways 
(modified from Jiménez-Fernández et al, 
2015).  Free radicals, H2O2: hydrogen 
peroxide; NO: nitric oxide; O2: oxygen; 
O2
−: superoxide radical; OH−: hydroxide 




−: nitrate; 8-OHdG: 8-hydroxy-2’-
deoxyguanosine; TBARS: thiobarbituric 
acid reactive substances.  Antioxidant 
enhancing-enzymes, CAT: catalase; GPX: 
glutathione peroxidase; GR: glutathione 
reductase; SOD: superoxide dismutase; 
XO: xanthine oxidase.  Antioxidants, 
GSH: reduced glutathione; GSSG: oxidized 
glutathione; UA: uric acid
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A recent meta-analysis37 reported that some inflammatory me-
diators and some neurotrophins specifically change according to the 
polarity/affective stability of individuals with BD. The same study 
found that the oxidative stress parameter TBARS was elevated in 
both mania and depression, but not in euthymia. Because there is 
no single, reliable oxidative stress biomarker, a combination of sev-
eral biomarkers would be helpful to differentiate affective phases. 
Thus, the aim of the present study was to analyze and synthesize 
existing evidence on oxidative stress markers and antioxidant pa-
rameters in patients with BD during its different polarities.
2  | METHOD
This meta-analysis was performed following the preferred report-
ing items for systematic reviews and meta-analyses (PRISMA) state-
ments of quality.38
2.1 | Search strategy
An electronic literature search without language restrictions was con-
ducted from data inception until 06/30/2019 in MEDLINE/PubMed, 
Cochrane Library, Scopus, and TripDatabase. The search was supple-
mented by a manual search of reference lists of included and relevant 
review articles. The search terms used were: 1) oxidative stress, anti-
oxidant*, nitrosative stress, nitrative stress, nitro-oxidative stress, free radi-
cal*, and different oxidative stress markers, including malondialdehyde 
(MDA), thiobarbituric acid reactive substances (TBARS), nitric oxide 
(NO), SOD, CAT, glutathione peroxidase (GPX), glutathione disulfide 
(GSSG), glutathione (GSH), uric acid, and zinc; and 2) bipolar disorder and 
related disorders (bipolar disorder, mania, mixed episodes, maniform 
episode). If data needed for the meta-analysis were missing, authors 
of identified studies were contacted to obtain them.
2.2 | Study selection/inclusion criteria
Inclusion criteria were: (a) patients diagnosed with BD; (b) quantita-
tive data (mean ± SD) for oxidative stress markers or antioxidant 
levels in serum, plasma or red blood cells (RBC); (c) data available in 
a healthy control (HC) group in cross-sectional and in longitudinal 
studies at baseline, and/or (d) follow-up data available before and 
after treatment (antidepressants, mood stabilizers, or lithium and 
antipsychotic drugs) in longitudinal studies of BD patients. Studies 
where patients with BD had any other important psychiatric physical 
disease that could potentially affect oxidative stress were excluded.
2.3 | Data extraction and outcomes
Selected data on oxidative stress markers and antioxidants were 
extracted and entered by one author (S.J-F.), with a second author 
(D.G-R) verifying the information. All inconsistencies were resolved 
by consensus.
2.4 | Quality assessment of included studies
To assess study quality, we followed guidelines from the 
Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE), with the following items being required 
in a high-quality study39: (a) clear description of patient inclusion 
criteria and, for case-control studies, case ascertainment based 
on psychometric methods and comparable control selection; (b) 
diagnosis and measurement of BD utilizing reliable instruments; 
(c) clear description of oxidative stress measurements; (d) clear de-
scription of how BD and oxidative stress variables were handled 
in the analyses; and (e) control for potential confounders, either 
by exclusion criteria or statistical adjustment, including smoking 
status, body mass index (BMI) or obesity, recent infections, other 
chronic medical diseases, or the use of medication, each of which 
can affect oxidative stress.
2.5 | Data analysis
Oxidative stress and antioxidant parameters were meta-analyzed 
separately if data were provided in ≥3 studies. The following 
meta-analyses were performed: (a) patients with BD compared 
with HCs; (b) patients with BD, stratified by mania, bipolar de-
pression, or euthymia, each in comparison with HC; (c) patients 
with BD before and after treatment; and (e) in patients with BD 
and HC SOD and CAT were meta-analyzed together to compare 
overall antioxidant status.
We calculated standardized mean differences (SMD) weighted 
for sample size [±95% confidence intervals (CI)]. Heterogeneity 
among studies was explored by means of a χ2 test of homogeneity 
together with the I2 statistic (a P < .05 and an I2 ≥ 50% indicating 
significant heterogeneity). First, we pooled data from BD patients 
regardless of the sample source for the analyses of the target param-
eters, ie, serum, plasma, whole blood, or RBC) If a study presented 
data from more than one of the four possible sources, we used data 
from the source used by most of the remaining studies for that spe-
cific outcome.
We also conducted the following subgroup analyses: (a) mania, 
bipolar depression, euthymia, medication free-mania, and treat-
ed-mania, each in comparison with HC; and (b) according to the sam-
ple source (ie, serum, plasma, whole blood, or RBC). Most data were 
extracted from serum and plasma. Finally, after pooling SOD and 
CAT data from patients with BD in comparison with HCs, data were 
analyzed regarding antioxidant status. We used funnel graphs (trial 
effect against trial size) to investigate the likelihood of publication 
bias. All data were analyzed with Review Manager 5.2 (http://commu 
nity.cochr ane.org/); analyses were two-sided, with alpha = 0.05 and 
without correction for multiplicity.
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3  | RESULTS
3.1 | Search results
Of 2,748 hits, 2,616 articles were excluded based on title and ab-
stract review. Of the 132 potentially eligible studies, 84 were ex-
cluded after full-text review for the following reasons (Figure 2): (a) 
data were not related to oxidative stress parameters or were not 
from plasma, serum or RBC (29 articles); (b) duplicated articles (20 
articles); (c) lack of an HC group (15 articles); (d) no meta-analyzable 
data (9 articles); (e) genetic studies, cultured cells, in-vitro studies, 
post-mortem studies, or review articles (6 articles); or (f) diagnosis 
other than BD (5 articles). This selection yielded 48 eligible articles 
that correspond to 44 studies (Table S1).
According to the five requirements considered by the STROBE 
group, the global quality of the studies included in the analysis was 
medium to high (Table S1). Only 12 (27.3%) studies met all the quality 
criteria and only one (2.3%) met <3 characteristics. The methods/
sources of participant selection were not clearly defined in five stud-
ies (11.4%) and assessment of BD was unclear in six (13.6%) stud-
ies. Description of oxidative stress measures was provided clearly 
in all studies, except seven (15.9%). The handling of BD and oxida-
tive stress in the analyses was not described in two studies (4.5%) 
(Table S1).
3.2 | Study, patient, and blood source 
characteristics
The characteristics of the 1,979 patients and the 1,788 HCs are pre-
sented in Table 1.
Patients and HCs were matched on: (a) gender and age in 18 stud-
ies (40.9%); (b) gender, age and smoking in seven studies (15.9%); (c) 
gender, age, BMI, and smoking in one study (2.3%); whereas match-
ing criteria were neither mentioned nor applied in 10 studies (22.7%).
DSM-IV was used to diagnose BD in 42 studies (95.5%). The 
distribution of studies, according to oxidative stress markers, blood 
source and diagnosis are provided in Table S2 and the description of 
each individual study included in the meta-analysis is presented in 
Table S3.
3.3 | Individual parameters of all BD patients 
compared to HCs
Compared with HCs, patients with BD had higher levels of MDA 
(SMD = 0.80; 95% CI, 0.18 to 1.42; P = .01; I2 = 93%), TBARS 
(SMD = 1.00; 95% CI, 0.62 to 1.39; P = .01; I2 = 92%) and nitrites 
(SMD = 1.04; 95% CI, 0.78 to 1.31; P < .0001; I2 = 23%) (Table 2). 
After excluding one poor quality study (analyzed studies n = 13), 
F I G U R E  2   Flow chart
Records identify by 
database search
(n=2748)
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results continued being significant for TBARS (SMD = 1.02; 95% CI, 
0.61 to 1.42; P < .0001; I2 = 92%).
Compared with HCs, patients with BD had higher levels of the 
non-enzymatic antioxidants uric acid (SMD = 0.61; 95% CI, 0.32 to 
0.89; P < .0001; I2 = 82%) that remained significant after excluding 
one poor quality study (analyzed studies n = 10) (SMD = 0.54; 95% 
CI, 0.27 to 0.82; P = .03; I2 = 79%). Moreover, BD patients had 
significantly higher activity of the enzymatic antioxidants CAT 
(SMD = 1.36; 95% CI, 0.25 to 2.48; P = .02; I2 = 98%) and GST 
(SMD = 2.49; 95% CI, 0.58 to 4.39; P = .01; I2 = 98%), and lower lev-
els the non-enzymatic antioxidant GSH (SMD=−0.48; 95% CI, −0.14 
to −0.83; P = .006; I2 = 78%), without differences in both zinc levels 
(SMD=−0.06; 95% CI, –0.68 to 0.56; P = .85; I2 = 87%) and the activ-
ity of the enzymatic antioxidants SOD (SMD = 0.46; 95% CI, –0.10 
to 1.02; P = .10; I2 = 95%) and GPX (SMD = 0.24; 95% CI, –0.32 to 
0.81; P = .40; I2 = 93%).
Compared with HCs, the antioxidant status (pooling SOD and 
CAT antioxidant enzymes in studies that assessed and reported 
both SOD and CAT activity) was significantly increased in BD 
(SMD = 0.63; 95% CI, 0.05 to 1.20; P = .03; I2 = 95%).
Stratifying the analysis by sample source, comparing to HCs, 
TBARS levels remained significantly higher, with a large effect 
size, although the result remained heterogeneous (plasma: six 
studies; n = 234; SMD = 0.97; 95% CI, 0.36 to 1.57; P = .002; 
I2 = 86%; serum: seven studies; n = 537; SMD = 1.02; 95% CI, 
0.52 to 1.53; P < .001; I2 = 94%) without differences between 
both subgroups (P = .98). Regarding uric acid levels, only plas-
ma-derived results remained significant (plasma: four studies; 
n = 121; SMD = 1.21; 95% CI, 0.19 to 2.22; P = .02; I2 = 92%; 
serum: four studies; n = 183; SMD = 0.43; 95% CI, −0.35 to 
1.21; P = .028; I2 = 93), with significant subgroup differences 
(P < .0001). This subgroup difference remained significant after 
excluding 1 low-quality study (P = .03).
Stratifying the analyses by sample source, the differences be-
tween BD and HCs remained non-significant for SOD [(plasma: 
four studies; n = 129; SMD = 0.28; 95% CI, –0.71 to 1.27; P = .58; 
I2 = 92%; serum: eight studies; n = 342; SMD = 0.52; 95% CI, –0.44 
to 1.48; P = .29; I2 = 97%; RBC: five studies; n = 111; SMD = 0.66; 
95% CI, –0.44 to 1.75; P = .24; I2 = 93%); and for GPX (serum: three 






Age, mean (SD) 36.1 (9.2) 33.9 (8.5)
Age according to BD phase, 
mean (SD)
Mania (16 studies, 406 
patients)
31.7 (8.3) –
Depression (10 studies, 
317 patients)
36.0 (8.8) –
Euthymia (23 studies, 921 
patients)
39.0 (9.9) –
Female gender, % 53.2 48.94
BMI, mean (SD) 25.6 (4.2) 24.1 (3.6)
Smoking status (yes), % 43.3 26.9
Illness duration (years), mean 
(SD)
12.3 (7.8) –
YMRS (baseline), mean (SD) 13.1 (4.6) –
HDRS (baseline), mean (SD) 10.65 (4.8) –
Treatment (baseline), % 74.4 –




Abbreviations: BD, bipolar disorder; BMI, Body Mass Index; HDRS, 
Hamilton Depression Rating scale; YMRS, Young Mania Rating Scale.











CI P value I2
GST 3 214 2.49 0.58 4.39 .01 98%
CAT 8 346 1.36 0.25 2.48 .02 98%
Nitrites 5 194 1.04 0.78 1.31 <.0001 23%
TBARS 13 771 1.00 0.62 1.39 <.0001 92%
MDA 8 370 0.80 0.18 1.42 .01 93%
SOD+CAT 7 273 0.63 0.05 1.20 .03 95%
Uric acid 11 612 0.61 0.32 0.89 <.0001 82%
SOD 17 471 0.46 –0.10 1.02 .10 95%
GPX 11 377 0.24 –0.32 0.81 .40 93%
GSH 8 317 –0.48 -0.14 -0.83 .006 78%
Zinc 2 156 –0.06 –0.68 0.56 .85 87%
Note: The parameters are presented in descending order of the standardized mean differences.
Abbreviations: CAT, catalase; GPX, glutathione peroxidase; GST, glutathion transferase; MDA, malondialdehyde; SOD, superoxide dismutase; TBARS, 
thiobarbituric acid reactive substances.
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studies; n = 167; SMD= –0.26; 95% CI, −1.07 to 0.57; P = .52; 
I2 = 94%; RBC: five studies; n = 111; SMD = 0.85; 95% CI, −0.22 to 
1.92; P = .12; I2 = 94%)].
3.4 | Comparison of patients according to the 
BD polarity
Compared to HCs, MDA levels were not significantly different in eu-
thymia (SMD = 0.48; 95% CI, −0.11 to 1.07; P = .11; I2 = 92%).
Compared with HCs, TBARS levels were significantly higher in 
mania, bipolar depression, and euthymia (mania: SMD = 1.87; 95% 
CI, 1.07 to 2.68; P < .0001; I2 = 90%; depression: SMD = 0.92; 
95% CI, 0.12 to 1.72; P = .02; I2 = 92%; euthymia: SMD = 0.39; 
95% CI, 0.03 to 0.76; P = .04; I2 = 74%), without differences be-
tween mania and bipolar depression (P = .10) or bipolar depres-
sion and euthymia (P = .24). However, compared to HCs, TBARS 
levels were higher in patients in mania than in euthymia (P < .001) 
(Table 3).
Compared with HCs, uric acid levels were significantly higher 
in mania and euthymia (mania: SMD = 1.13; 95% CI, 0.83 to 1.44; 
P < .0001; I2 = 41%; euthymia: SMD = 0.67; 95% CI, 0.05 to 1.28; 
P = .03; I2 = 82%) but not in bipolar depression (SMD = 0.08; 95% CI, 
−0.27 to 0.42; P = .67; I2 = 39%). Subgroup analyses showed signifi-
cant differences between mania and bipolar depression (P < .0001), 
but not between mania and euthymia (P = .18) or bipolar depression 
and euthymia (P = .10) (Table 3).
Compared with HCs, GSH levels were significant lower in 
patients with euthymia (SMD=−0.29; 95% CI, −0.53 to −0.04; 
P = .02; I2 = 8%) but without differences in patients with mania 
(SMD = −0.33; 95% CI, −1.21 to 0.54; P = .45; I2 = 88%) and be-
tween them (P = .92).
Compared with HCs, SOD levels did not significantly differ 
in patients with mania, bipolar depression, and euthymia (mania: 
SMD = 0.92; 95% CI, −0.08 to 1.92; P = .07; I2 = 95%; depression: 
SMD = 0.11; 95% CI, −3.44 to 3.66; P = .95; I2 = 98%; euthymia: 
SMD = 0.32; 95% CI, −0.35 to 0.98; P = .35; I2 = 92%) and SOD was 
similar among them (mania vs depression P = .67; mania vs euthymia 
P = .33; depression vs euthymia P = .54) (Table 3).
Compared with HCs, CAT levels did not significantly differ in 
patients with mania, depression, or euthymia (mania: SMD = 1.31; 
95% CI, −0.35 to 2.98; P = .12; I2 = 98%; depression: SMD = 2.00; 
95% CI, −0.12 to 4.12; P = .06; I2 = 97%; euthymia: SMD = 0.97; 95% 
CI, −1.53 to 3.46; P = .45; I2 = 98%), and the CAT activity was sim-
ilar among them (mania vs depression P = .62; mania vs euthymia 
P = .82; depression vs euthymia P = .54).
Similarly, compared with HCs, GPX did not significantly differ in 
patients with mania, depression, or euthymia (mania: SMD = −0.09; 
95% CI, −1.12 to 0.95; P = .87; I2 = 96%; depression: SMD = 0.60; 
95% CI, −0.51 to 1.70; P = .29; I2 = 86%; euthymia: SMD = 0.59; 
95% CI, −0.22 to 1.41; P = .16; I2 = 82%), and the GPX activity was 
similar among them (mania vs depression P = .73; mania vs euthymia 
P = .31; depression vs euthymia P = .99).
Compared with HCs, zinc levels in patients with bipolar depres-
sion were significantly lower (SMD = −0.59; 95% CI, −0.90 to −0.27; 
P < .001; I2 = 0%), but the analysis only included two studies.
Compared with HCs, the antioxidant status (pooling SOD and 
CAT), pooled SOD + CAT levels were significantly higher in patients 
with mania or depression pooled (SMD = 1.05; 95% CI, 0.28 to 1.81; 
P = .007; I2 = 96%), without significant differences in patients with 
euthymia (SMD = −0.31; 95% CI, −1.01 to 0.39; P = .39; I2 = 88%). 
The antioxidant status was higher in patients with depression or 
mania pooled together than those with euthymia (P = .01), although 
the antioxidant status was similar between patients with mania and 
patients with depression (P = .48).
3.5 | Cross-sectional comparison of medicated 
vs unmedicated patients with mania compared to 
healthy controls
Stratifying manic BD patients by treatment status, compared to HCs, 
manic patients without treatment had a significantly higher SOD activ-
ity (SMD = 1.23; 95% CI, 0.21 to 2.26; P = .02), while manic patients on 
treatment did not differ from HCs (SMD = 0.92; 95% CI, −1.73 to 3.56; 
P = .50), but without subgroup differences (P = .83) (Figure 3A).
Similarly, compared to HCs, manic patients without treatment 
had a significantly lower GPX activity (SMD = −1.06; 95% CI, −1.39 
to −0.72; P < .00001; I2 = 0%), while manic patients on treatment did 
not differ from HCs (SMD = 0.64; 95% CI, −0.93 to 2.20; P = .50), in 
this case with significant subgroup differences (P = .043) (Figure 3B).
3.6 | Longitudinal comparison of patients 
before and after psychotropic treatment; and cross-
sectional comparison of patients after psychotropic 
treatment, each compared to healthy controls
3.6.1 | Study and patient characteristics
Altogether, eight studies provided data in patients with BD 
(n = 511; age = 30.5 ± 8.5 years; 36.2% female, mean illness dura-
tion = 9.2 ± 5.7 years; based on three studies with data) before and 
after treatment (mean treatment duration: 10.4 weeks). DSM-IV crite-
ria were used for BD diagnosis in all eight studies. At baseline, patients 
were medication-free in five studies (62.5%); in the three remaining 
studies, 47.1% of patients were on antipsychotics, 20.7% on lithium, 
22.1% on other mood stabilizers, and 19.1% on antidepressants.
The mean HDRS scores in the two studies with both baseline 
and endpoint data decreased from 22.6 ± 3.6 to 16.2 ± 1.6, and the 
mean YMRS scores in three studies decreased from 25.14 ± 7.05 to 
4.53 ± 3.97 points.
These studies reported two enzymes involved in antioxidant 
peripheral defenses: SOD (six studies; three analyzing outcomes in 
serum, two in plasma, and one in RBC), and GPX (three studies, each 
analyzing outcomes in plasma, serum, and whole blood).
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TA B L E  3   Oxidative stress parameters and antioxidants in patients with bipolar disorder, stratified by different illness phases/polarity, 










95% CI P value I2 P value
MDA
Euthymia 6 332 0.48 –0.11 1.07 .11 92%
TBARS
Mania 5 143 1.87 1.07 2.68 <.0001 90% M vs D: P = .10; M 
vs E: P = .0001
Depression 5 161 0.92 0.12 1.72 .02 92% D vs E: P = .24
Euthymia 9 321 0.39 0.03 0.76 .04 75%
Uric acid
Mania 5 160 1.13 0.83 1.44 <.001 41% M vs D: P < .0001; 
M vs E: P = .18
Depression 3 91 0.08 –0.27 0.42 .67 39% D vs E: P = .10
Euthymia 4 135 0.67 0.05 1.28 .03 82%
GSH
Mania 3 78 –0.33 –1.21 0.54 .45 88% M vs E: P = .92
Euthymia 3 147 –0.29 –0.53 -0.04 .02 8%
SOD
Mania 7 192 0.92 –0.08 1.92 .07 95% M vs D: P = .67; M vs 
E: P = .33
Depression 3 79 0.11 –3.44 3.66 .95 98% D vs E: P = .91
Euthymia 7 285 0.32 –0.35 0.98 .35 92%
CAT
Mania 5 152 1.31 –0.35 2.98 .12 98% M vs D: P = .62; M 
vs E: P = .82
Depression 3 74 2.00 –0.12 4.12 .06 97% D vs E: P = .54
Euthymia 4 120 0.97 –1.53 3.46 .45 98%
SOD+CAT
Mania 4 130 0.87 –0.05 1.79 .06 96% M + D vs E: P = .01
M+D 6 180 1.05 0.28 1.81 .007 96% D vs E: P = .48
Euthymia 3 93 0.97 –0.31 –1.01 .39 88%
GPX
Mania 6 177 –0.09 –1.12 0.95 .87 96% M vs D: P = .37; M 
vs E: P = .31
Depression 2 50 0.60 –0.51 1.7 .29 86% D vs E: P = .99
Euthymia 3 72 0.59 –0.22 1.41 .16 82%
Zinc
Depression 2 85 –0.59 –0.90 -0.27 <.001 0%
Parameters according 









95% CI P value I2 P value
SOD
With treatment 3 76 0.92 –1.73 3.56 .50 98% With vs without: 
P = .83Without treatment 4 86 1.23 0.21 2.26 .02 90%
GPX
With treatment 4 109 0.64 –0.93 2.20 .43 97% With vs without: 
P = .04Without treatment 3 68 –1.06 –1.39 –0.72 <.001 0%
(continues)
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3.6.2 | Enzymatic antioxidants: superoxide 
dismutase and glutathione peroxidase
After psychotropic treatment, no significant change was found in ei-
ther SOD activity (six studies; n = 143 evaluated twice; SMD = 0.35; 
95% CI, –0.57 to 1.28; P = .45; I2 = 93%) or GPX activity (three studies; 
n = 67 evaluated twice; SMD=–0.10; 95% CI, –0.24 to 0.45; P = .56; 
I2 = 0%). For SOD, analyses were stratified by sample source and BD 
polarity, but results remained non-significant (serum: three studies; 
n = 81 patients evaluated twice; SMD = 0.46; 95% CI, –1.54 to 2.47; 
P = .65; I2 = 97%; and mania: four studies: n = 85 patients evaluated 
twice; SMD = 0.64; 95% CI, –0.57 to 1.96; P = .34; I2 = 93%).
Altogether, there were no differences in either parameters after 
treatment when compared with HCs for either SOD (six studies; 
F I G U R E  3   Antioxidant enzyme activity in patients with mania treated with medication and mania without treatment compared with 
healthy controls. (A) Superoxide dismutase (SOD), (B) Glutathione peroxidase (GPX)
Parameters before 
and after treatment No. studies No patients SMD
Lower 95% 
CI Higher 95% CI P value I2
SOD
Before vs After 6 143 0.35 –0.57 1.28 .45 93%
After vs. HCs 6 139 –0.26 –1.17 1.19 .76 96%
GPX
Before vs After 3 67 –0.10 –0.24 0.45 .56 0%
After vs. HCs 3 63 –0.41 –1.77 0.96 .55 93%
Abbreviations: CAT, catalase; GPX, glutathione peroxidase; GSH, glutathione; SMD, standardized mean differences; SOD, superoxide dismutase; 
TBARS, thiobarbituric acid reactive substances. Significant P values are in bold font.
TA B L E  3   Continued
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n = 139; SMD= –0.26; 95% CI, –1.17 to 1.19; P = .72; I2 =96%) or 
GPX (three studies; n = 63; SMD= –0.41; 95% CI, –1.77 to 0.96; 
P = .55; I2 = 93%).
4  | DISCUSSION
4.1 | Main findings
In this meta-analysis, we studied oxidative stress parameters as 
trait markers of BD and state markers of affective phases/polarity. 
We found an increase in the oxidative stress parameters MDA and 
TBARS, supporting previous results.36 After restricting the analyses 
to different illness polarities (mania, depression, euthymia), TBARS 
was increased in mania, depression and euthymia (with significantly 
higher levels in mania vs euthymia). These results indicate that TBARS 
is an oxidative stress trait marker of BD. However, the significantly 
greater elevation in TBARS levels in mania than euthymia prevents 
us from rejecting its additional role as a state marker, as has been 
suggested previously by Tsai and Huang 40 and by Machado-Viera.41
Similarly, we found a significant decrease in GSH and increase 
in uric acid in patients with mania and euthymia compared to HCs. 
Our result is consistent with data indicating that uric acid is signifi-
cantly higher in BD than HCs,42 while this is not the case for un-
ipolar depression.94 Both antioxidants GSH and uric acid could be 
considered trait markers of BD, as they appear to be decreased and 
increased, respectively, in euthymia. Moreover, it seems that GSH is 
not affected by the age at BD onset, as reported by an English study 
comparing 26 early-onset with 20 late-onset BD patients that did 
not find significant group differences in GSH.43
Nitrites were also significantly elevated in patients with BD, al-
though stratified analyses based on polarity could not be performed 
due to the limited number of studies. However, nitrite levels have 
been reported to reduce with treatment,44 an isolated finding that 
we could not meta-analyze.
Moreover, compared with HCs, patients with BD had signifi-
cantly increased GST and CAT antioxidant enzymes. However, in 
the stratified analysis by polarity, CAT was not significantly different 
from HCs anymore in either patients with mania or bipolar depres-
sion, but these findings could be due to reduced statistical power of 
the subgroup analyses.
For the present study, data were available to stratify patients 
with mania based on psychotropic treatment status. In analyses of 
patients with mania, those without treatment (compared with HCs) 
showed a significant increase in SOD and a significant decrease in 
GPX. However, in patients on psychotropic treatment, SOD and GPX 
activities were not different from HCs.
Until now, studies have reported contradictory data about the 
implication of the antioxidant enzyme GPX during mania and the ef-
fect of medication.40,45 Similarly, despite our findings of treatment 
effects in the cross-sectional comparison of treated vs untreated 
samples of BD patients with mania, our meta-analysis in longitudinal 
studies did not identify significant changes in the activity of the two 
analyzed oxidative antioxidant enzymes, SOD and GPX, compared 
to HCs. This divergent result, together with the lack of differences 
in the other antioxidants, could mean that there is no significant 
change in those parameters. Alternatively, this lack of a treatment 
effect in longitudinal studies could be due to the limited number of 
studies included in the analysis and the difficulties in controlling for 
confounding factors, highlighting the limitation of not being able to 
meta-analyze every enzyme in light of illness duration or the number 
of previous affective episodes. For example, the number of lifetime 
affective episodes have been negatively correlated with the activity 
of GPX,34 which seems to indicate that there is a deterioration of 
the antioxidant mechanism and an accumulation of allostatic load 
with illness progression.46 Furthermore, other potential confound-
ing factors that must be considered in future research include de-
mographic and environmental factors, such as gender, age, diet, or 
smoking habits.47-50 Finally, our difficulty to find differences based 
on psychotropic treatments, which were heterogenous, as likely the 
treatment response would have been too, does not imply that they 
do not exist. For example, it has been shown that the therapeutic 
effect of lithium is associated with changes in the levels of different 
antioxidants, such as SOD and CAT,41 and that valproate can have a 
similar effect.51 Therefore, future studies should report results sep-
arately for different psychotropic treatments.
Finally, the combined analysis of SOD + CAT activity, which is 
a measure of antioxidant status, showed a significant increase in 
patients with BD vs HCs. A previous study found an elevated total 
antioxidant capacity in patients with BD vs HCs, irrespective of the 
number of manic episodes.52 In our analysis, increased SOD + CAT 
activity was also observed in patients with a symptomatic affective 
phase of the disease, but not in those with euthymia, with differ-
ences according to manic or depressive polarity. The combination 
of SOD + CAT could therefore be suggested as a state marker of 
affective disease, which is different in euthymia.
Our results are consistent with the hypothesis that oxidative 
stress is associated with BD and extend the existing findings by an 
enriched database and stratified analyses by polarity/illness phase 
and treatment. Oxidative stress is characterized by an increase in 
free radicals, which attack proteins, DNA, and lipids. Subsequently, 
there is an increase in different substances formed by the conversion 
of molecules, including MDA or TBARS, which are produced by lipid 
peroxidation of the cellular bilayer. The organism compensates for this 
excess through the action of different blood antioxidants, such as uric 
acid and bilirubin, or by the action of buffering substances, like GSH 
and different antioxidant enzymes.18 All antioxidants, especially an-
tioxidant enzymes, work in a coordinated manner. For example, GPX 
has a regular activity of scavenging free radicals that are constantly 
formed in the organism, while CAT works in acute situations, when 
there is cellular oxidative stress.18 Our results support this explana-
tion: we confirmed an increase in the products of lipid peroxidation 
(MDA, TBARS) and nitrites, and an enhancement of the CAT enzyme 
in patients with BD compared with HCs which counteract oxidative 
stress. However, it has been suggested that CAT activity correlates 
negatively with the duration of BD, but not with age of onset of the 
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disease.53 Due to this fact, we could explain the lack of significance 
when we analyzed CAT stratified by different BD phases, as there 
was no specific change according to different illness polarities, and 
patients in different disease stages were pooled together. The de-
creased GPX activity in untreated patients with mania might be due 
to a consumption of the enzyme at that moment, characterized by an 
oxidative stress status, as the remaining parameters suggest.
Our results are similar to the findings of two other meta-analyses 
in BD,35,36 although unlike those authors, we conducted subgroup 
analyses according to bipolar illness polarity in order to reduce the 
heterogeneity of the patient sample and analyses. Altogether, the 
alterations in oxidative stress markers and antioxidants are not ex-
clusive to BD. Similar findings have been described in patients with 
depression and schizophrenia.54,55 For example, an increase of lipid 
peroxidation products and alterations in the antioxidant enzyme 
SOD has been reported in both disorders.55 Furthermore a decrease 
of GPX activity has been reported in acutely relapsed patients with 
schizophrenia, an increase of SOD activity in patients with a first 
episode of psychosis, and low zinc levels in unipolar disorder.54 
Within BD, at least some oxidative stress markers, such as TBARS, 
uric acid, zinc, and SOD+CAT, may be specific to either mania and/or 
depression, while others may not, such as GSH, SOD, CAT, and GPX. 
However, it is also possible that the statistical power was insufficient 
to identify significant differences from HCs in thee subgroup anal-
yses by polarity, as suggested by the positive results when pooling 
SOD+CAT, while differences between BD and HCs in these enzyme 
activities alone did not reach statistical significance. Nevertheless, 
it is possible that the pro-oxidative balance is related to the acuity 
of the disease or the intensity of the associated anxiety and related 
stress.56 Conversely, uric acid, on the other hand, may be a trait 
marker of BD, as uric acid appears to be increased in mania as well as 
in euthymia compared with HCs.
In this sense, our results are consistent with those of Bartoli 
et al,42,57 who reported that, in comparison with HCs, patients 
with mania and depression had higher uric acid levels. Conversely, 
patients with unipolar depression and those with a relapse after a 
first-episode psychosis or schizophrenia had lower levels.54,55 Thus, 
uric acid could possibly be a reliable biomarker helping to make an 
early diagnosis and, by means of early treatment initiation, may pro-
mote a favorable course of the disease.58
Altogether, our results are important because they support the 
hypothesis that BD is related to oxidative and nitrosative stress. 
Free radicals are a consequence of aerobic metabolism and they are 
counterbalanced by complex mechanisms, involving enzymatic and 
non-enzymatic scavengers. High levels of free radicals attack cellular 
compounds (lipids, proteins, and DNA) and enhance the activation of 
the immune-inflammatory system.59-61 The central nervous system, 
and especially the brain, is very vulnerable to oxidative stress due to 
its high lipid content, rapidly attacked by free radicals, or its lower 
level of CAT.20 Therefore, free radicals can result in cell alteration 
and cell dysfunction, triggering a neuro-degenerative process.62,63 
In BD, this imbalance would be aggravated by the loss in efficacy of 
antioxidant enzymes as the number of episodes increases.34
4.2 | Strengths and limitations of our study
Strengths of this study include some relevant differences com-
pared to previous meta-analyses of oxidative stress markers and 
antioxidants in BD patients compared with HCs.43,44 To control for 
patient heterogeneity, we performed stratified analyses according 
to the affective phase/polarity of BD whenever possible, ie, mania, 
bipolar depression and euthymia. Our selection criteria were more 
stringent, as we only included studies reporting data from blood 
sources, avoiding antioxidant levels in post-mortem brains, as they 
are more appropriate for studying structural consequences of oxi-
dative stress.64 Our selection criteria were more stringent, as we 
only included studies reporting data from blood sources, avoiding 
antioxidant levels in post-mortem brains, as they are more appro-
priate for studying structural consequences of oxidative stress.64 
Differences in methodology and laboratory technology used in 
biochemical parameters could potentially affect the results, but 
this possibility was mitigated by stringent inclusion criteria, as-
sessing study quality and heterogeneity, and conducting subgroup 
and sensitivity analyses where necessary. Finally, we performed 
cross-sectional and longitudinal analyses to study the effect of 
psychotropic drugs on oxidative stress markers and, especially the 
antioxidant enzymes.
There is a recent meta-analysis that evaluated uric acid in pa-
tients with BD according to the affective phases of the disorder.42 
Our study enriched the knowledge reported by Bartoli and co-work-
ers42 by analyzing, together with uric acid, three additional oxida-
tive stress parameters (MDA, TBARS and nitrites), four antioxidant 
enzymes (SOD, CAT, GPX, GST), two non-enzymatic antioxidants 
(GSH, zinc), and the pooled activity of two antioxidant enzymes, 
SOD and CAT, as markers of the antioxidant status of BD patients.
Despite the above strengths, the results of the present me-
ta-analysis should be interpreted within its limitations. First, despite 
the comprehensive systematic search, there were still limited num-
bers of studies and included participants, especially for the strati-
fied subgroup and treatment effect analyses. Second, results were 
mostly highly heterogeneous, which sometimes continued after per-
forming stratified analyses according to illness polarity/illness phase. 
Third, different confounding factors not considered in the individual 
research studies may potentially affect oxidative stress parameters, 
including illness duration or acuity, blood sample sources, employed 
assays, and different patient-related factors, such as sgender, age, 
smoking status, or BMI.54,53,49,47 Fourth, we could not take into ac-
count genetic factors, as depression and BD are related to different 
polymorphisms in pro-oxidant and antioxidant genes that seems to 
increase the susceptibility to develop either BD or unipolar depres-
sion.65-67 Fifth, in longitudinal analyses, there were insufficient data 
to compare specific kinds of treatments and their possible differ-
ential effects (antipsychotics, antidepressants, and mood-stabi-
lizing agents, including antiepileptics and lithium), although all of 
them have shown antioxidant properties.68 Sixth, only 12 (27.3%) 
of the meta-analyzed studies were of “high quality”, fulfilling all 
criteria. Seventh, despite changes in the activity of the enzymatic 
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antioxidants SOD and GPX demonstrated in mania without treat-
ment, the results could not be extrapolated to patients with bipolar 
depression because less than three studies reported such data.
5  | CONCLUSION AND FUTURE 
DIREC TIONS
Although our results support the hypothesis that oxidative stress 
plays an important role in BD, based on other work, it seems that 
there is some overlap with other psychiatric disorders, eg, depres-
sion and psychosis,54,55 as also shown for inflammatory markers.69 
Therefore, more studies that simultaneously measure blood oxi-
dative stress and immune/inflammatory parameters across diag-
nostic boundaries may be helpful to establish disease-specific 
biomarkers. The need to assess the ‘oxidative stressosome’ and in-
flammosome broadly and, ideally, concurrently, is especially impor-
tant because there is likely no single biomarker of oxidative stress, 
and the combination of several parameters is bound to be more in-
formative.20 Our results add to the accumulating body of evidence 
new insights about oxidative stress trait or state biomarkers in BD 
in general and based on illness polarity. To our knowledge, only uric 
acid had been studied as trait/state biomarker in BD before, and 
our results for TBARS and SOD+CAT, could add to this literature 
as being possible trait and state markers. Moreover, our results on 
SOD and GPX in mania with and without treatment seem to sup-
port a relevant restorative treatment effect. Future studies should 
take into account confounding factors that can modify oxidative 
stress status. As mentioned above, researchers should simultane-
ously measure oxidative stress markers and antioxidants, but also 
in different blood sources, as it is unlikely that a single biomarker 
of oxidative stress is going to be helpful diagnostically or as an in-
tervention target or stratifying biomarker of the illness and treat-
ment response. Regarding treatments, although antioxidants –for 
instance N-acetylcysteine (NAC) or poly-unsaturated fatty acids 
(PUFA)– have reported contradictory results in patients with BD, 
antioxidants used as adjunctive therapy added to antidepressants 
have shown promising results in BD depression,70,71 which should 
be followed up in future studies. Importantly, such studies should 
select patients based on a certain predefined minimum threshold 
of oxidative status in order to enrich samples for the proposed 
biological target mechanism of the tested intervention. Much of 
the contradictory findings in the literature regarding antioxidant 
or anti-inflammatory agents may well be due to the fact that the 
oxidative and/or inflammatory status of included patients in such 
studies varied widely.
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